D
8.07
0.07 (0.88%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Bearish |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | Delcath Systems, Inc. | Bullish | - |
Stockmoo Score
0.6
|
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Hunting Hill Global Capital, Llc | 31 Mar 2024 | 104,398 |
| Levin Capital Strategies, L.P. | 31 Mar 2024 | 54,969 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Stephens & Co., 209.79%) | Buy |
| Median | 22.00 (172.62%) | |
| Low | 18.00 (Craig-Hallum, 123.05%) | Buy |
| Average | 21.67 (168.53%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 7.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 28 Jun 2024 | 18.00 (123.05%) | Buy | 8.37 |
| HC Wainwright & Co. | 15 May 2024 | 22.00 (172.61%) | Buy | 7.19 |
| Stephens & Co. | 14 May 2024 | 25.00 (209.79%) | Buy | 7.07 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 Jul 2024 | Announcement | Delcath Systems to Host Second Quarter 2024 Earnings Call |
| 28 May 2024 | Announcement | Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath’s Board of Directors |
| 14 May 2024 | Announcement | Delcath Systems Reports First Quarter 2024 Results and Business Highlights |
| 07 May 2024 | Announcement | Delcath Systems to Host First Quarter 2024 Earnings Call |
| 06 May 2024 | Announcement | Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT |
| 03 May 2024 | Announcement | Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |